(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s new class-action lawsuit against three makers of insulin drug products:

“While we’re still reviewing the details of the lawsuit – in which pharmacy benefit managers (PBMs) are not named as defendants – it inexplicably attacks prescription drug rebates, long used to reduce costs in public programs like Medicaid and in the commercial market.

While none of America’s largest, most sophisticated health purchasers – including Fortune 500 companies, health plans, and Medicare Part D plans – are required to use the services of a PBM, almost all choose to because they reduce costs and improve the quality of benefits.”